# Elucidation of New Phosphorylation Site of the EWS/ATF1 Fusion Oncoprotein in Clear Cell Sarcoma

> **NIH NIH R03** · NORTH CAROLINA STATE UNIVERSITY RALEIGH · 2022 · $76,000

## Abstract

Abstract
Clear cell sarcoma (CCS) is an aggressive bone and soft tissue cancer of young adults. It is caused by gene
fusions between EWS (Ewing’s sarcoma oncogene) and ATF1 (activating transcription factor) or CREB
(cAMP-responsive element binding protein), giving rise to chimeric oncoproteins consisting of the N-terminal
EWS domain fused to a C-terminal half of truncated ATF1 and CREB domains. The chimeric EWS/ATF1 and
EWS/CREB oncoproteins are potent transcription factors that bind to CRE (cAMP-responsive element) via the
ATF1 and CREB domains. Normal human ATF1 and CREB are activated by stimulus-induced phosphorylation,
in which ATF1 at Ser63 and CREB at Ser133 are phosphorylated by protein kinase A (PKA) or related kinases
in response to various growth factors and hormones. In contrast, the molecular mechanism through which the
transcription function of EWS/ATF1 and EWS/CREB is regulated remains unknown. The primary reason for
this problem is the fact that truncated ATF1 and CREB domains fused to EWS do not contain these canonical
Ser63 and Ser133 PKA-mediated phosphorylation sites. However, we recently identified the conserved new
phosphorylation sites in the chimeric oncoproteins of ATF1 at Ser198 and CREB at Ser271. Intriguingly, we
found that HIPK2 (homeodomain interacting protein kinase 2), but not PKA, phosphorylates EWS/ATF1 at
Ser198 of the ATF1 domain and suppresses the transcription of c-FOS, one of the key EWS/ATF1 target
genes driving aggressive cell proliferation of CCS. Indeed, EWS/ATF1 can be phosphorylated at Ser198 of the
ATF1 domain in human CCS cells. Furthermore, we preliminary identified candidates of ATF1 Ser198
phosphatases. Thus, we have found two new potential reversible regulators of EWS/ATF1 oncoprotein
through Ser198 phosphorylation. We will test our hypothesis that the phosphorylation status of EWS/ATF1 at
Ser198 determines the EWS/ATF1 transcription activity on key target genes responsible for aggressive
proliferation of CCS cancer cells. We will characterize the phosphorylation and dephosphorylation of
EWS/ATF1 at Ser198 associated with its transcription function and CCS malignant phenotype. As ATF1 and
CREB contain highly conserved phosphorylation sites, we anticipate the same regulatory mechanism of the
EWS/CREB fusion oncoprotein via Ser271 phosphorylation in the truncated CREB domain. HIPK2 as well as
Ser198 ATF1 phosphatases characterized in this proposal can be a new molecular target for more selective
and effective inactivation of these fusion oncoproteins in CCS.
1

## Key facts

- **NIH application ID:** 10513111
- **Project number:** 1R03CA262935-01A1
- **Recipient organization:** NORTH CAROLINA STATE UNIVERSITY RALEIGH
- **Principal Investigator:** YOSHIAKI TSUJI
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $76,000
- **Award type:** 1
- **Project period:** 2022-08-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10513111

## Citation

> US National Institutes of Health, RePORTER application 10513111, Elucidation of New Phosphorylation Site of the EWS/ATF1 Fusion Oncoprotein in Clear Cell Sarcoma (1R03CA262935-01A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10513111. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*